Literature DB >> 11485211

The complement system in central nervous system diseases.

H Rus1, F Niculescu.   

Abstract

The activation of complement system is an important factor participating in inflammatory, neurodegenerative, and cerebrovascular diseases. Astrocytes and neurons are able to synthesize complement components. Myelin and oligodendrocyte (OLG) activate the classical pathway of complement in vitro in the absence of antibodies. Sublytic C5b-9 in the absence of cell death induces proto-oncogenes, activates cell cycle, and enhances cell survival in OLG. In addition, C5b-9 reverses the differentiation phenotype in OLG and enhances cell survival. beta amyloid protein is an activator of the complement system and neurons are susceptible to bystander complement mediated damage. These findings indicate that complement activation and membrane assembly of C5b-9 play an important role in pathogenesis of central nervous system (CNS) disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11485211     DOI: 10.1385/IR:24:1:79

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  50 in total

1.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.

Authors:  D R Wren; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.

Authors:  S K Singhrao; J W Neal; B P Morgan; P Gasque
Journal:  Exp Neurol       Date:  1999-10       Impact factor: 5.330

3.  Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases.

Authors:  M E Sanders; E L Alexander; C L Koski; M L Shin; Y Sano; M M Frank; K A Joiner
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation.

Authors:  L Soane; H Rus; F Niculescu; M L Shin
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

5.  Neurons express proteins of the classical complement pathway in Alzheimer disease.

Authors:  K Terai; D G Walker; E G McGeer; P L McGeer
Journal:  Brain Res       Date:  1997-09-26       Impact factor: 3.252

6.  Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.

Authors:  C L Koski; A E Estep; S Sawant-Mane; M L Shin; L Highbarger; G M Hansch
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

7.  Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.

Authors:  N J Scolding; B P Morgan; W A Houston; C Linington; A K Campbell; D A Compston
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

8.  Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

9.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Proliferation of mature oligodendrocytes after trauma to the central nervous system.

Authors:  S K Ludwin
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

View more
  8 in total

1.  Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.

Authors:  Jeban Ganesalingam; Jiyan An; Christopher E Shaw; Gerry Shaw; David Lacomis; Robert Bowser
Journal:  J Neurochem       Date:  2011-03-21       Impact factor: 5.372

2.  Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis.

Authors:  Cornelia Cudrici; Takahiro Ito; Ekaterina Zafranskaia; Susanna Weerth; Violeta Rus; Hegang Chen; Florin Niculescu; Katerina Soloviova; Cosmin Tegla; Adrian Gherman; Cedric S Raine; Moon L Shin; Horea Rus
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

3.  Selective accumulation of the complement membrane attack complex in aging choriocapillaris.

Authors:  Kathleen R Chirco; Budd A Tucker; Edwin M Stone; Robert F Mullins
Journal:  Exp Eye Res       Date:  2015-09-11       Impact factor: 3.467

Review 4.  Complement activation in the injured central nervous system: another dual-edged sword?

Authors:  Faith H Brennan; Aileen J Anderson; Stephen M Taylor; Trent M Woodruff; Marc J Ruitenberg
Journal:  J Neuroinflammation       Date:  2012-06-21       Impact factor: 8.322

5.  Pathological Features of Enterovirus 71-Associated Brain and Lung Damage in Mice Based on Quantitative Proteomic Analysis.

Authors:  Yuefei Jin; Dong Li; Tiantian Sun; Yue Du; Yanlei Gao; Ronghua Ding; Wangquan Ji; Weiguo Zhang; Haiyan Yang; Shuaiyin Chen; Guangcai Duan
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

6.  Complement factor C5a and C5a receptor contribute to morphine tolerance and withdrawal-induced hyperalgesia in rats.

Authors:  Yan-Hua Li; Hua Jin; Jing-Shu Xu; Guang-Qiong Guo; DA-Lin Chen; Yun Bo
Journal:  Exp Ther Med       Date:  2012-07-10       Impact factor: 2.447

7.  Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line.

Authors:  Tokihiko Sawada; Osamu Yamada; Naoko Yoshimura; Keiko Hatori; Shohei Fuchinoue; Satoshi Teraoka
Journal:  Cancer Cell Int       Date:  2002-10-03       Impact factor: 5.722

8.  Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury.

Authors:  Hal X Nguyen; Manuel D Galvan; Aileen J Anderson
Journal:  J Neuroinflammation       Date:  2008-06-25       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.